Risk stratification tools are frequently used to help guide treatment decisions after first relapse in multiple myeloma. Researchers have developed a new risk stratification tool consisting of 4 distinct dimensions that is used to characterize survival expectations.
Abemaciclib demonstrated efficacy and an acceptable safety profile in treating brain metastases in hormone receptor (HR)-positive/HER2-negative breast cancer, but was not effective for brain metastases in HR-positive/HER2-positive breast cancer.
MonarchE is an ongoing, open-label phase 3 study designed to evaluate invasive disease-free survival in patients with hormone receptor‒positive, HER2-negative advanced breast cancer receiving abemaciclib plus standard-of-care adjuvant endocrine therapy (ET).
Abemaciclib, but not ribociclib or palbociclib, exhibits inhibition of CDK4/6 plus kinases other than CDK4/6, and induces cell death rather than cytostasis, which may be therapeutically advantageous in patients with hormone receptor‒positive breast cancer that is generally resistant to CDK4/6 inhibitors.
Researchers report the results of a phase 2 study evaluating the tolerability and long-term outcomes using a combination of ixazomib plus cyclophosphamide and low-dose dexamethasone in newly diagnosed multiple myeloma (MM) patients who are not eligible for transplant.
Adherence to prescribed therapy is pivotal in cancer treatment. To ensure that patients receive the full benefit of their prescribed therapy, nurses and nurse practitioners play a critical role in identifying adverse events and implementing effective interventions that balance efficacy and tolerability.
Results of this randomized, placebo-controlled phase 3 trial showed that avatrombopag was superior to placebo in terms of the cumulative number of weeks with a platelet response, platelet response at day 8, and durability of platelet response in patients with refractory chronic immune thrombocytopenia (ITP).